RT Book, Section A1 Elkayam, Uri A1 Pizula, Jena A2 Fuster, Valentin A2 Narula, Jagat A2 Vaishnava, Prashant A2 Leon, Martin B. A2 Callans, David J. A2 Rumsfeld, John S. A2 Poppas, Athena SR Print(0) ID 1202455328 T1 Peripartum Cardiomyopathy T2 Fuster and Hurst's The Heart, 15e YR 2022 FD 2022 PB McGraw-Hill Education PP New York, NY SN 9781264257560 LK accesscardiology.mhmedical.com/content.aspx?aid=1202455328 RD 2024/04/18 AB Chapter SummaryThis chapter reviews the epidemiology, pathophysiology, and management of peripartum cardiomyopathy (PPCM), an idiopathic cardiomyopathy presenting with heart failure due to severe left ventricular systolic dysfunction. Presentation is usually during the first month after delivery but can be during the second or third trimester of pregnancy or a few months postpartum (see Fuster and Hurst’s Central Illustration). The incidence of PPCM in the United States is approximately 1 in 3000 live births and is significantly higher in Black women than in White women. The incidence worldwide varies and is higher in Africa and Haiti than in Europe and the United States. Risk factors for the condition include advanced age, preeclampsia, Black ethnicity, and multifetal pregnancy. Normalization of left ventricular function occurs in >50% of women in the United States, mostly within 2 to 6 months after diagnosis. Reported recovery rates in other countries vary. Although many patients do improve, PPCM can be associated with important and lasting complications. Moreover, subsequent pregnancy in women with a history of PPCM can be associated with relapse with reduced ejection fraction and worsening of symptoms; this is more likely in women with persistent left ventricular dysfunction prior to their subsequent pregnancy but occasionally occurs in women with recovered left ventricular function.